0.36
-0.0125(-3.36%)
Currency In USD
| Previous Close | 0.37 |
| Open | 0.37 |
| Day High | 0.38 |
| Day Low | 0.35 |
| 52-Week High | 1.3 |
| 52-Week Low | 0.22 |
| Volume | 259,593 |
| Average Volume | 1.7M |
| Market Cap | 7.86M |
| PE | -0.51 |
| EPS | -0.71 |
| Moving Average 50 Days | 0.37 |
| Moving Average 200 Days | 0.59 |
| Change | -0.01 |
If you invested $1000 in Adial Pharmaceuticals, Inc. (ADIL) since IPO date, it would be worth $3.55 as of October 19, 2025 at a share price of $0.36. Whereas If you bought $1000 worth of Adial Pharmaceuticals, Inc. (ADIL) shares 5 years ago, it would be worth $8.04 as of October 19, 2025 at a share price of $0.36.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
GlobeNewswire Inc.
Oct 17, 2025 1:00 PM GMT
GLEN ALLEN, Va., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and r
Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution
GlobeNewswire Inc.
Oct 09, 2025 12:30 PM GMT
Partnership has successfully completed analytical validation of a cheek swab collection solution for testing and identifying patients with the genotypes important for AD04 developmentGLEN ALLEN, Va., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmace
Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04
GlobeNewswire Inc.
Sep 16, 2025 12:00 PM GMT
FDA Minutes Reflect Constructive Dialogue and Successful Meeting Outcome with Alignment on Upcoming Phase 3 Clinical Trial Design for AD04 In Alcohol Use DisorderGLEN ALLEN, Va., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDA